Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Filings indexed 1,040 across all filing types
Latest filing 2026-04-13 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Regulatory Filings
2026-04-13 English
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Regulatory Filings
2026-03-31 English
SCHEDULE 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
Major Shareholding Notification
2026-03-31 English
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Regulatory Filings
2026-03-30 English
EFFECT - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Regulatory Filings
2026-03-30 English
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Regulatory Filings
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.